Great interview with CEO Gary Rabin on Seeking Alpha today.
Gary was saying they are talking with China about partnering, I hope not, China will screw ACTC. A partnership with anyone but China would be great.
Advanced Cell Technology (ACTC.OB) is
a biotechnology company focused on the development and commercialization of
human embryonic and adult stem cell technology in the field of regenerative
medicine. Their main focus revolves around macular degeneration, which is an
unmet medical need for the world worth well over $30 billion. ACTC has treated
nine patients between their three ongoing trials. All of the patients are
reported as doing remarkably well, and there have been no safety issues
whatsoever. The most exciting thing to report is that the success rate is
running at 100% for those treated. Obviously there is much more to the story,
and if interested, then one should view the ACTC website and presentations for a
greater understanding
That up the share price just a little to closed at 0.0813 on 2.7 million shares. The three month avg. is 5.2 million shares.
Geron down 4 cents at $1.72 on 764,592 shares. The three month avg. volume is 712,632 shares. It's just a waiting game, good result in Dec 2012 we move up to $3 to $5, poor results 3 to 5 cents.
I love AAPL up $ 15.73 to close $610.75. It's going higher
Good luck in this rigged casino,
Tuesday, July 31, 2012
Geron beats by 1 cent misses on rev
I listened to the call, trials are moving along, 3 Phase 2 trials results Dec 2012, 1 Phase 2 trial [breast cancer] 1st quarter 2013 and 2 Phase 2 [with GRN1005] in the 2nd quarter of 2013. No good news. Chip stated no Phase 3 trials without a partner. Geron has money for the Phase 2 trials only. If results are good Geron will find a partner if not they are done as a company. No deal on the stem cell property.
Good luck in this rigged casino,
Good luck in this rigged casino,
Monday, July 30, 2012
Geron earnings call July 31 at 9AM EST
Very disappointed, no follow through on Geron. It went down 8 cents to close at $1.76 on 775,131 shares. The three month avg. volume is 706,581 shares. I was very close to selling a few covered but chickened out. Now lets hope Chip has some thing good to say.
ACTC closed at 0.0808 should be moving up a little with the trials moving foreword.
AAPL you got to love it up $9.87 to close at $595.03. on 13.5 million shares. The three month avg. volume is 15.6 million shares.
Good luck in this rigged casino,
ACTC closed at 0.0808 should be moving up a little with the trials moving foreword.
AAPL you got to love it up $9.87 to close at $595.03. on 13.5 million shares. The three month avg. volume is 15.6 million shares.
Good luck in this rigged casino,
ACTC treats 10th patient in Embryonic Stem Cell Trials
ACT Treats 10th Patient in Embryonic Stem Cell Trials for Macular Degeneration
Jul 30, 2012 08:30:01 (ET)
MARLBOROUGH, Mass., Jul 30, 2012 (BUSINESS WIRE) -- Advanced Cell Technology, Inc. ("ACT"; OTCBB: ACTC), a leader in the field of regenerative medicine, today announced treatment of the final patient in the first patient cohort in its Phase 1/2 clinical trial for Stargardt's macular dystrophy (SMD) using retinal pigment epithelial (RPE) cells derived from human embryonic stem cells (hESCs). The surgery was performed on Friday, July 27 at Moorfields Eye Hospital in London, the same site as the first two treatments, by a team of surgeons led by Professor James Bainbridge, consultant surgeon at Moorfields and Chair of Retinal Studies at University College London. The outpatient transplant surgery was performed successfully without any complications, and the patient is recovering uneventfully. This is the tenth patient overall to now be treated with the RPE cell therapy developed by the company.
"Our European trial is making very steady progress, having now completed enrollment of the first patient cohort," commented Gary Rabin, chairman and CEO. "We are very encouraged and look forward to receiving clearance to initiate the treatment of the second patient cohort in the coming weeks."
The Phase 1/2 trial is designed to determine the safety and tolerability of hESC-derived RPE cells following sub-retinal transplantation in patients with SMD at 12 months, the study's primary endpoint. It will involve a total of 12 patients, with cohorts of three patients each in an ascending dosage format. It is similar in design to the U.S. trial for SMD that was initiated in July 2011.
"This is a significant month for the company," continued Mr. Rabin. "One year ago we treated the first of our patients in our two U.S. clinical trials. The one-year follow-up for those initial patients indicates that the improvements in visual acuity we initially reported have in fact persisted now for a year. Indeed, we are consistently observing improvements in subjective and objective visual acuity for patients being treated at the various clinical centers involved in our trials. Again, these trials are still at very early stages, but these preliminary results indicate that we are on the right track."
The European Medicines Agency's (EMA) Committee for Orphan Medicinal Products (COMP) has officially designated ACT's human embryonic stem cell (hESC)-derived retinal pigment epithelial (RPE) cells as an orphan medicinal product for the treatment of SMD.
About Stargardt's Disease
Stargardt's disease or Stargardt's Macular Dystrophy is a genetic disease that causes progressive vision loss, usually starting in children between 10 to 20 years of age. Eventually, blindness results from photoreceptor loss associated with degeneration in the pigmented layer of the retina, called the retinal pigment epithelium, which is the site of damage that the company believes the hESC-derived RPE may be able to target for repair after administration.
About Advanced Cell Technology, Inc.
ACTC share price down a little. They are slowly moving foreword.
Geron up 3 cents, need more volume, will sell covered calls at $2
AAPL love the $10 move up.
Good luck in this rigged casino,
Jul 30, 2012 08:30:01 (ET)
MARLBOROUGH, Mass., Jul 30, 2012 (BUSINESS WIRE) -- Advanced Cell Technology, Inc. ("ACT"; OTCBB: ACTC), a leader in the field of regenerative medicine, today announced treatment of the final patient in the first patient cohort in its Phase 1/2 clinical trial for Stargardt's macular dystrophy (SMD) using retinal pigment epithelial (RPE) cells derived from human embryonic stem cells (hESCs). The surgery was performed on Friday, July 27 at Moorfields Eye Hospital in London, the same site as the first two treatments, by a team of surgeons led by Professor James Bainbridge, consultant surgeon at Moorfields and Chair of Retinal Studies at University College London. The outpatient transplant surgery was performed successfully without any complications, and the patient is recovering uneventfully. This is the tenth patient overall to now be treated with the RPE cell therapy developed by the company.
"Our European trial is making very steady progress, having now completed enrollment of the first patient cohort," commented Gary Rabin, chairman and CEO. "We are very encouraged and look forward to receiving clearance to initiate the treatment of the second patient cohort in the coming weeks."
The Phase 1/2 trial is designed to determine the safety and tolerability of hESC-derived RPE cells following sub-retinal transplantation in patients with SMD at 12 months, the study's primary endpoint. It will involve a total of 12 patients, with cohorts of three patients each in an ascending dosage format. It is similar in design to the U.S. trial for SMD that was initiated in July 2011.
"This is a significant month for the company," continued Mr. Rabin. "One year ago we treated the first of our patients in our two U.S. clinical trials. The one-year follow-up for those initial patients indicates that the improvements in visual acuity we initially reported have in fact persisted now for a year. Indeed, we are consistently observing improvements in subjective and objective visual acuity for patients being treated at the various clinical centers involved in our trials. Again, these trials are still at very early stages, but these preliminary results indicate that we are on the right track."
The European Medicines Agency's (EMA) Committee for Orphan Medicinal Products (COMP) has officially designated ACT's human embryonic stem cell (hESC)-derived retinal pigment epithelial (RPE) cells as an orphan medicinal product for the treatment of SMD.
About Stargardt's Disease
Stargardt's disease or Stargardt's Macular Dystrophy is a genetic disease that causes progressive vision loss, usually starting in children between 10 to 20 years of age. Eventually, blindness results from photoreceptor loss associated with degeneration in the pigmented layer of the retina, called the retinal pigment epithelium, which is the site of damage that the company believes the hESC-derived RPE may be able to target for repair after administration.
About Advanced Cell Technology, Inc.
ACTC share price down a little. They are slowly moving foreword.
Geron up 3 cents, need more volume, will sell covered calls at $2
AAPL love the $10 move up.
Good luck in this rigged casino,
Saturday, July 28, 2012
Geron up 8% good volume
Geron closed up 14 cent at $1.84 on 1,626,251 shares. The three month avg. volume is 688,470 shares. The earnings call is July 31 at 9AM. If we get more volume, say close to 2 million shares Monday with a price of $2.00+ then just maybe some thing good is coming. I will sell a few covered calls if we get a price over $2.00. Geron was in an article called "5 Biotech Stocks Poised for Breakout" at the Street. Stated that $2.22-$2.60 is the next level, if we get more volume and a breakout above $1.89.
ACTC was down just a little at 0.082 on 3.3 million shares. The three month avg. is 5.2 million shares.
AAPL was up $10.25 to close at $585.16 on 14.4 million shares. Still the best company out there.
Good luck in this rigged casino,
ACTC was down just a little at 0.082 on 3.3 million shares. The three month avg. is 5.2 million shares.
AAPL was up $10.25 to close at $585.16 on 14.4 million shares. Still the best company out there.
Good luck in this rigged casino,
Thursday, July 26, 2012
Geron earnings call July 31
Geron closed at 6 1/2 cents at $1.695 on 477,878 shares. The three month avg. is 688,470 shares. I will be listening July 31 at 9 AM EST. I don't think there will be any great news, hope I'm wrong.
ACTC up 4.62% to close at 0.0837 on 3.8 million shares. The three month avg. is 5.2 million shares. Waiting waiting waiting
AAPL down 9 cents at $574.88 on 14.5 million shares. The three month avg. is 15.7 million shares.
Good luck in this rigged casino.
ACTC up 4.62% to close at 0.0837 on 3.8 million shares. The three month avg. is 5.2 million shares. Waiting waiting waiting
AAPL down 9 cents at $574.88 on 14.5 million shares. The three month avg. is 15.7 million shares.
Good luck in this rigged casino.
ACTC issued patent for Human RPR Cells
ACT Issued Broad Patent for Human RPE Cells Derived From All Types of Pluripotent Stem Cells
New Australian Patent Covers Human RPE Cells Made From Range of Pluripotent Stem Cells, Including Both Embryonic Stem Cells and induced Pluripotent Stem (iPS) Cells
“We continue to make great progress with our patent estate covering RPE therapies,” said Gary Rabin, chairman and CEO of ACT. “Our ongoing success in securing broad patent protection around the world, including this newly-issued Australian patent, is a testament to our innovative chief scientific officer, Dr. Robert Lanza, and the rest of our scientific team.”
The efficient production of highly pure RPE cell preparations represents a critical step in the creation of renewable sources of transplantable cells that can be used to target degenerative diseases of the eye such as Stargardt’s Macular Dystrophy (SMD) and dry Age-related Macular Degeneration (dry AMD).
“Our current embryonic stem cell trials pave the way for other pluripotent stem cell therapies,” commented Dr. Lanza. “ACT’s cellular reprogramming technologies using iPS cells are in an advanced stage of development, and we hope to be in a position to move toward clinical translation in the not-too-distant future. Since iPS cells can be made from the patient’s own cells such as skin or blood cells they may allow us to expand our cell therapies beyond immune-privileged sites such as the eye without the risk of immune rejection.”
Mr. Rabin concluded, “We are aggressively pursuing patent protection for a variety of aspects of our programs. Our intellectual property strategy includes both vigilance in pursuing comprehensive coverage from our initial patent filings, such as this new Australian patent, and filing for protection around our scientific team’s various innovations. At the same time we are paying close attention to including within our patent coverage those ways others may wish to adapt our technology for commercial use, such as through the choice of stem cell source, or the use of solid supports or cell suspensions for delivery. Following this strategy, we are establishing both formidable barriers-to-entry for potential competitors, as well as strong potential licensing opportunities for others, translating into solid revenue generation possibilities for the company.
This is good news the stock price is up just a little, due to all the things that must happen for this company to survive. Need more good results from Phase 1/2, needs a partner, need a reverse split to get on the big broad. This company is a roll of the dice. I have 25,000 shares riding on that roll.
Good luck in this rigged casino,
The efficient production of highly pure RPE cell preparations represents a critical step in the creation of renewable sources of transplantable cells that can be used to target degenerative diseases of the eye such as Stargardt’s Macular Dystrophy (SMD) and dry Age-related Macular Degeneration (dry AMD).
“Our current embryonic stem cell trials pave the way for other pluripotent stem cell therapies,” commented Dr. Lanza. “ACT’s cellular reprogramming technologies using iPS cells are in an advanced stage of development, and we hope to be in a position to move toward clinical translation in the not-too-distant future. Since iPS cells can be made from the patient’s own cells such as skin or blood cells they may allow us to expand our cell therapies beyond immune-privileged sites such as the eye without the risk of immune rejection.”
Mr. Rabin concluded, “We are aggressively pursuing patent protection for a variety of aspects of our programs. Our intellectual property strategy includes both vigilance in pursuing comprehensive coverage from our initial patent filings, such as this new Australian patent, and filing for protection around our scientific team’s various innovations. At the same time we are paying close attention to including within our patent coverage those ways others may wish to adapt our technology for commercial use, such as through the choice of stem cell source, or the use of solid supports or cell suspensions for delivery. Following this strategy, we are establishing both formidable barriers-to-entry for potential competitors, as well as strong potential licensing opportunities for others, translating into solid revenue generation possibilities for the company.
This is good news the stock price is up just a little, due to all the things that must happen for this company to survive. Need more good results from Phase 1/2, needs a partner, need a reverse split to get on the big broad. This company is a roll of the dice. I have 25,000 shares riding on that roll.
Good luck in this rigged casino,
Subscribe to:
Posts (Atom)